In partnership with
The Bottom Line Upfront 💡
Cigna $CI ( ▲ 1.6% ) has transformed from a traditional insurer into America's third-largest healthcare services platform, generating $8.4B in annual free cash flow by processing 1.6 billion pharmacy claims. Trading at a massive discount despite strong fundamentals, the stock offers 360-687% upside potential if management successfully navigates regulatory headwinds and executes their rebate-free pharmacy strategy.
Sponsorship
Stop optimizing for clicks. Start driving pipeline.
Rising costs. Signal loss. Platform changes. Most paid media fails because it's built for clicks, not revenue.
On April 27th, HubSpot's former Head of Paid breaks down the exact framework for structuring campaigns that drive real pipeline in 2026. 20 minutes. Live Q&A. Free.
Strata Layers Chart
Layer 1: The Business Model 🏛️
Think of Cigna as the middleman who makes healthcare actually work—and takes a cut at every step. While most people know them as a health insurance company, they've evolved into something much more interesting: a healthcare services platform that touches nearly every part of your medical experience.
The Three-Ring Circus:
🎪 Ring 1: Evernorth Health Services ($172B in revenue) This is where the real magic happens. Evernorth processes over 1.6 billion pharmacy claims annually—that's like handling every prescription filled by half of America. When you pick up your blood pressure medication at CVS, there's a good chance Cigna processed that claim, negotiated the price with the drug manufacturer, and took a small fee from your employer's health plan. They also run specialty pharmacies for expensive cancer drugs and rare disease treatments, where margins are much juicier.
🎪 Ring 2: Cigna Healthcare ($36B in revenue) The traditional insurance business—collecting premiums and paying medical claims. Think of it as a giant risk pool where healthy people subsidize sick people, and Cigna keeps the difference when medical costs stay below premium collections. They recently sold their Medicare Advantage business for $4.9B, essentially saying "we'd rather focus on employer-sponsored plans where we have more control."
🎪 Ring 3: Other Operations ($521M in revenue) The miscellaneous stuff—corporate-owned life insurance, some run-off businesses, and other odds and ends they're slowly winding down.
How They Actually Make Money:
Processing fees on every prescription claim (think credit card processing, but for pills)
Manufacturer rebates (drug companies pay them for favorable formulary placement)
Insurance underwriting profits (premiums minus medical costs)
Specialty pharmacy margins (much higher than regular prescriptions)
Key Internal Metrics They Obsess Over:
Pharmacy claim volume (1.6B+ annually) - more claims = more fees
Medical care ratio (83.3% currently) - medical costs as % of premiums (lower is better)
Adjusted income from operations ($5.9B) - their preferred profit metric
Customer retention rates - switching health plans is a massive pain
Key Takeaway: Cigna makes money by being the essential plumbing of American healthcare—processing claims, negotiating prices, and managing risk across a $4 trillion industry.
Layer 2: Category Position 🏆
Cigna operates in a healthcare oligopoly where size matters enormously. The bigger you are, the better rates you can negotiate with hospitals, drug companies, and pharmacies. It's like being in a poker game where the house always wins, but some houses are bigger than others.
The Big Players:
UnitedHealth Group (~$400B revenue) - The 800-pound gorilla with OptumRx and massive provider networks
CVS Health (~$370B revenue) - Owns Aetna insurance plus retail pharmacies and PBM Express Scripts
Cigna (~$200B revenue) - The scrappy third-place player with strong employer relationships
Humana (~$100B revenue) - Medicare specialist
Anthem/Elevance (~$170B revenue) - Regional insurance powerhouse
Cigna's Competitive Advantages:
Scale in pharmacy benefits - One of the "Big Three" PBMs alongside Express Scripts and OptumRx
Employer relationships - Strong with large corporations who value integrated solutions
Data integration - Can use pharmacy data to predict medical costs and vice versa
Less retail exposure - Unlike CVS, they're not trying to run corner drugstores
Recent Competitive Moves:
✅ Renewed major client contracts through 2030 (good news for revenue stability)
✅ Invested $2B in Shields Health Solutions (specialty pharmacy play)
❌ Sold Medicare Advantage business (retreating from a growing market)
🤔 Announced "rebate-free" pharmacy model (bold but risky differentiation)
The industry is consolidating rapidly, with everyone trying to become a one-stop healthcare shop. Cigna's betting they can compete by being really good at the behind-the-scenes stuff rather than owning everything.
Key Takeaway: Cigna is a strong #3 player in a consolidating industry, with solid competitive moats but facing pressure from larger, more integrated rivals.
Layer 3: Show Me The Money! 📈
Cigna's financial story is tale of two businesses: a growing pharmacy services juggernaut and a shrinking but profitable insurance operation.
Revenue Breakdown (9 months 2025):
Pharmacy revenues: $158.3B (78% of total) ↗️ 17%
Insurance premiums: $31.0B (15% of total) ↘️ 10%
Fees and other: $12.4B (6% of total) ↗️ 14%
Investment income: $707M (0.3% of total) ↗️ 2%
The Pharmacy Growth Engine: Evernorth is absolutely crushing it with 16% revenue growth driven by:
New customer wins and organic growth
Higher drug utilization (people taking more medications)
Specialty pharmacy expansion (those $10,000/month cancer drugs)
"Affordability services" (fancy term for rebate optimization)
The Insurance Reality Check: Healthcare premiums dropped 10% due to the Medicare Advantage sale, but the remaining business shows mixed signals:
Medical care ratio jumped to 83.3% ↗️ (bad - means medical costs are eating into profits)
Stop-loss insurance seeing higher claims than expected
Individual plans struggling with adverse selection
Margin Story:
Overall operating margin: 3.4% (thin but consistent)
Evernorth margin: 2.9% (lower but growing on massive scale)
Healthcare margin: 9.5% (higher but shrinking business)
Cost Structure:
Pharmacy/service costs: $157.2B (77% of revenue) - mostly pass-through
Medical costs: $26.1B (13% of revenue) - the big variable
SG&A expenses: $11.0B (5% of revenue) - being optimized via restructuring
Cash Generation Machine:
Operating cash flow: $3.5B (down from $5.2B due to timing)
Free cash flow: ~$8.4B annually (strong and consistent)
Share buybacks: $2.6B in 9 months (returning cash to shareholders)
Key Takeaway: Cigna is transforming from a traditional insurer into a pharmacy services powerhouse, trading lower-margin but massive-scale revenue for higher-margin but shrinking insurance profits.
Layer 4: Long-Term Valuation (DCF Model) 💰
The Verdict: Significantly Undervalued 🎯
Key Valuation Drivers:
Massive free cash flow generation ($8.4B+ annually) with consistent conversion
Low systematic risk (beta of 0.27) suggests premium valuation warranted
Diversified revenue streams reducing single-point-of-failure risk
Terminal growth assumptions of 2.5-3.5% (reasonable for healthcare services)
Why So Cheap? The market seems to be pricing in worst-case scenarios around healthcare regulation, PBM scrutiny, and the complexity of the business model. But the fundamentals suggest this pessimism is overdone.
Recommendation: The DCF analysis indicates substantial undervaluation even under conservative assumptions.
Layer 5: What Do We Have to Believe? 📚
Bull Case 🚀
The rebate-free pharmacy model works: If Cigna can successfully differentiate by eliminating traditional rebate structures, they could gain market share and improve margins while appearing more transparent to customers
Specialty pharmacy keeps growing: As medicine gets more personalized and expensive, Cigna's specialty capabilities become increasingly valuable, commanding premium pricing
Healthcare consolidation benefits scale players: Smaller competitors get squeezed out, leaving more business for the remaining giants like Cigna
Bear Case 🐻
Regulatory crackdown on PBMs: Government could force transparency that eliminates profitable rebate practices or break up integrated models entirely
Medical cost inflation accelerates: If healthcare costs spike faster than premium increases, the insurance business could become unprofitable
Competition from tech giants: Amazon, Google, or other tech companies could disrupt traditional healthcare intermediaries with direct-pay models
The Bottom Line: Cigna is betting they can evolve from a traditional insurer into a essential healthcare services platform. The pharmacy business is already proving this thesis, generating massive scale and steady profits. The question is whether they can maintain their competitive position as the industry consolidates and regulators circle. At current prices, you're getting a lot of upside if they execute successfully, with limited downside given their strong cash generation.
What to Watch 👀
📊 Medical Care Ratio: Currently 83.3% - watch for this to stabilize below 85%. Higher ratios mean medical costs are eating profits.
💊 Pharmacy Claim Volume: Growing 4% annually - acceleration above 6% would signal strong market share gains.
🏥 Evernorth Margin Trends: Currently 2.9% - the rebate-free model transition could temporarily pressure margins before improving them.
💰 Free Cash Flow Conversion: Target $8B+ annually - any significant decline could signal operational issues.
🏛️ Regulatory Developments: Watch for PBM legislation, Medicare Advantage rule changes, and any antitrust actions against healthcare consolidation.
🤝 Major Contract Renewals: Large employer contracts typically run 3-5 years - wins/losses here move the needle significantly.
Remember: Healthcare is a long-term game where relationships, scale, and data matter more than quarterly fluctuations. Cigna's betting on being indispensable infrastructure in a $4 trillion industry—and at these prices, that bet looks pretty attractive. 🎯
AI-written, human-approved
Disclaimer: This guide is for informational purposes only and does not constitute financial advice, investment recommendations, or an offer or solicitation to buy or sell any securities. The information contained in this report has been obtained from sources believed to be reliable, but StrataFinance does not guarantee its accuracy, completeness, or timeliness.